Federated Learning in Pharma: Privacy-Preserving AI Across Organizations

What Federated Learning Actually Is

Federated learning is a machine learning approach where models are trained across multiple decentralized data sources without moving the data itself to a central location. Instead of sending data to a centralized training environment, the model is sent to where the data lives. Local training produces model updates — gradients, weights, or other parameters — which are then aggregated to produce an improved global model. The data never leaves its source environment.

The basic federated learning workflow has several stages. A starting model is distributed to each participating data holder. Each participant trains the model on their local data, producing local updates. The updates are sent to a coordinator (or aggregated through cryptographic protocols that don’t require a trusted coordinator). The aggregated update is applied to produce a new global model, which becomes the starting point for the next round. Many rounds produce a model that has learned from the union of the distributed datasets.

Several variants exist, with different trade-offs. Horizontal federated learning trains across organizations that have similar data structures but different records — different hospital networks with similar patient data structures, for instance. Vertical federated learning trains across organizations that have different features about the same entities — a pharma company and a clinical lab with different data about the same patients. Federated transfer learning combines federated learning with transfer learning techniques to address situations where participants have heterogeneous data.

Federated learning is often combined with additional privacy-preserving techniques. Differential privacy adds calibrated noise to ensure that individual records can’t be reconstructed from model outputs. Secure multi-party computation provides cryptographic protocols for aggregation without a trusted central party. Homomorphic encryption allows computation on encrypted data. Each of these adds privacy guarantees at the cost of additional computational overhead and complexity.

Why Pharma Has a Particular Interest

Pharma’s interest in federated learning is driven by structural realities of the industry’s data landscape. Several of these realities make federated approaches particularly attractive.

Much pharma data cannot be centralized for legal, contractual, or competitive reasons. Patient data carries privacy obligations that often prevent transfer outside the originating institution. Trial data is governed by complex consent and contractual arrangements. Manufacturing data carries trade secret protections. Competitive data — chemical libraries, assay results, target validation data — has strategic value that prevents organizations from sharing it openly. Federated learning offers a way to extract insights from data that cannot be centralized.

The combined pharma data ecosystem is far larger than any single organization’s internal data. The chemical, assay, clinical, real-world, and manufacturing data scattered across pharma companies, academic institutions, and CROs vastly exceeds what any one organization owns internally. Models trained on the combined data can be substantially more capable than models trained on any single organization’s slice — a capability advantage that creates real strategic incentive to find mechanisms for combining without combining.

Privacy and consent regimes are tightening, not loosening. GDPR, HIPAA, and emerging frameworks in jurisdictions across the world impose increasing constraints on data transfer and use. Federated learning is one of the few approaches that scales well as these constraints tighten because it doesn’t depend on data centralization in the first place.

Industry consortia are increasingly collaborative on pre-competitive AI capability. MELLODDY, MELLODDY-TUDDI, and successor initiatives have demonstrated that pharma companies will collaborate on federated learning for pre-competitive use cases when the governance is right. This pattern is likely to expand as the technical and governance maturity grows.

Use Cases Where Federated Learning Adds Real Value

Federated learning is not a universal solution. It adds real value in specific use case categories with specific characteristics. The categories where federated learning is producing or could produce meaningful value in pharma include the following.

Within these categories, the use cases where federated learning produces the strongest results have specific characteristics: data heterogeneity that benefits from breadth, sufficient minimum useful data at each participant to train usefully, model architectures that work well in federated settings, and a governance regime that can sustain multi-party coordination. Use cases that lack these characteristics often produce disappointing federated outcomes even when the underlying technology is sound.

The MELLODDY example

The MELLODDY consortium is the most-cited pharma federated learning initiative because it demonstrated viability at meaningful scale. Ten major pharma companies trained a combined predictive model across distributed chemical and assay data — billions of data points that could not have been combined by any other mechanism. The published results showed performance improvements consistent with the increased data scale, validating the federated approach for this use case category. MELLODDY’s lessons — about governance design, technical architecture, and the human work required to sustain multi-party collaboration — are foundational reading for any organization considering federated initiatives in pharma.

Technical Architecture and Variants

The technical architecture of a pharma federated learning deployment involves several layers, each with design choices that affect performance, privacy, and complexity.

The federation topology defines who connects to what. Centralized topologies have a coordinator that aggregates updates from all participants. Decentralized or peer-to-peer topologies eliminate the coordinator using cryptographic protocols. Hybrid topologies use trusted aggregators for some operations and decentralized protocols for others. Each topology has different trust assumptions, infrastructure requirements, and governance implications.

The aggregation algorithm defines how local updates are combined. Federated averaging (FedAvg) is the simplest and most common, weighting updates by local data size. Variants like FedProx, FedNova, and federated optimization techniques address heterogeneity, drift, and convergence challenges. The right algorithm depends on the data heterogeneity across participants and the model architecture being trained.

The privacy layer adds protections beyond the basic federated workflow. Differential privacy, secure multi-party computation, and homomorphic encryption can be combined in various configurations to achieve different privacy guarantees at different computational costs. The right combination is specific to the regulatory and contractual requirements of the use case and the participants.

The infrastructure layer determines how training actually runs. Federated learning has more demanding infrastructure requirements than centralized training — secure communication, robust aggregation infrastructure, monitoring and observability across distributed participants, and operational tooling for handling failures and recovery. Building this infrastructure is a significant engineering investment.

Governance and Multi-Party Coordination

The technical complexity of federated learning is solvable. The governance complexity of multi-party federated learning is harder. Organizations evaluating federated learning often underestimate the governance investment required, with predictable disappointment.

The governance dimensions that have to be addressed include the following. Participation criteria — who can join, on what terms, with what data contribution requirements. Data and quality standards — what data each participant contributes, in what format, with what quality assurance. Use case selection — which models are trained federated, which remain organization-specific. IP and ownership — who owns the resulting model, how participants benefit from it, what IP protections govern derivative work. Operational governance — change management, version control, validation, and the day-to-day operations of the federation. Exit and unwind — how participants can leave, how the federation responds to participant exits, what happens to models and data when participants leave.

Each of these dimensions requires legal agreements, operational procedures, and ongoing relationship management across organizations that may also be competitors in their commercial activities. The governance work typically dominates the elapsed time of federated learning initiatives — and underinvestment in governance is the most common cause of stalled or failed deployments.

Regulatory and Validation Considerations

Federated learning in regulated pharma use cases adds layers of regulatory and validation consideration beyond what centralized approaches require. The dimensions that matter most include the following.

Data lineage and reproducibility. Validated AI models in pharma require demonstrable lineage from training data to model outputs. Federated learning makes lineage tracking harder because the training data is distributed and may not be directly accessible for retrospective analysis. Designing for lineage from the start — through metadata standards, audit trail capture, and reproducibility protocols — is essential.

Validation evidence in distributed settings. Validating a federated model requires evidence that it performs appropriately across the diversity of data sources, including data sources you may not directly control. The validation methodology has to address heterogeneity that centralized validation approaches don’t have to consider.

Change control across the federation. Model updates affect all participants. Change control protocols have to coordinate across organizations with different change control processes, regulatory contexts, and operational realities. The change control workload in a multi-party federation is materially higher than in a single-organization deployment.

Inspection readiness for participants. Each participating organization may face inspections that ask about federated learning use. The federation has to provide inspection-ready documentation that holds up across multiple regulatory contexts and inspection styles.

Cross-jurisdictional compliance. Federations that span jurisdictions face the union of compliance requirements across all jurisdictions involved. EU GDPR, US HIPAA, and other regimes interact in non-obvious ways when applied to federated computations, and legal analysis specific to each federation is essential.

Honest Limitations and Where It Doesn’t Help

Several limitations of federated learning in pharma deserve honest acknowledgment, both to set realistic expectations and to identify where centralized approaches remain preferable.

Communication overhead. Federated training requires substantially more communication than centralized training, which translates to longer wall-clock training times and infrastructure costs. For some model architectures, the overhead is prohibitive.

Convergence and stability. Federated training with heterogeneous data can have convergence and stability issues that centralized training doesn’t face. The mitigations exist but require expertise and tuning.

Privacy guarantees are bounded. Federated learning by itself doesn’t provide formal privacy guarantees — the model updates can leak information about the training data. Combining federated learning with differential privacy and secure aggregation provides stronger guarantees but at additional cost. Naïve federated learning without these additional protections is not a privacy-preserving solution despite the name.

Governance is hard and slow. Multi-party governance takes elapsed time that organizations consistently underestimate. Federated initiatives typically take twelve to twenty-four months from concept to operational deployment, with the governance work dominating the timeline.

Not all use cases benefit. Use cases where one organization has dominant data don’t benefit much from federated approaches. Use cases where data quality varies dramatically across potential participants face significant data quality coordination overhead. Use cases where models are commercially proprietary may not survive the IP discussions.

Federated learning is a powerful tool for the right use cases. It is not a universal solution, and treating it as one produces disappointment.

A Realistic Adoption Pathway

For pharma organizations evaluating federated learning, a realistic adoption pathway involves several stages that build capability and conviction over time.

Stage one is internal federated capability. Many organizations have data distributed across business units, geographies, or affiliates that face internal data movement constraints. Building internal federated capability — training models across internal but separated datasets — develops the technical and operational muscle for the more complex multi-party scenarios. The internal use case provides immediate value and creates the foundation for external work.

Stage two is bilateral federation with a single trusted partner. After internal capability is established, federation with a single partner — a trusted CRO, an academic collaborator, or a pre-competitive partner — extends the muscle to multi-party scenarios while keeping the governance complexity bounded.

Stage three is multi-party federation, often through a consortium structure. The complexity scales materially, but the technical and governance experience from earlier stages makes the work achievable. Organizations that try to start at stage three without the foundation of stages one and two typically struggle.

Stage four is mature federated capability across multiple use case categories. Organizations operating at this level have institutionalized federated learning as one tool in their AI portfolio, with clear criteria for when it adds value and when other approaches are preferable.

The pathway is multi-year. Organizations that try to compress it tend to skip the foundational stages and end up with disappointing results. Organizations that respect the pathway build durable capability that becomes a strategic asset over time.

Build versus join versus partner decisions

For organizations evaluating federated learning, an early strategic question is whether to build internal federated capability, join an existing consortium, or partner with a vendor that provides federated capability as a service. Each option has different cost, control, and strategic implications.

Building internal capability provides the most control and the deepest organizational learning but requires the largest upfront investment in technical capability, infrastructure, and governance design. The investment is justified for organizations that anticipate multiple federated use cases over time and want to build federation as a strategic capability.

Joining an existing consortium — MELLODDY-successor initiatives, disease-specific consortia, or therapeutic-area-specific collaborations — provides faster access to the value of federation at lower individual investment but with less control over governance, technical decisions, and strategic direction. The consortium model is well-suited to use cases where the value comes from the breadth of multi-party data and the strategic differentiation comes from elsewhere in the organization’s portfolio.

Partnering with a vendor that provides federated capability as a service offers the lowest barrier to entry but with vendor concentration risk, less control over the underlying technology choices, and ongoing vendor management overhead. The vendor partnership model is well-suited to organizations that want to evaluate federated learning before committing to deeper investment.

Most organizations end up with a portfolio across all three modes — internal capability for strategically important use cases, consortium participation for pre-competitive use cases where breadth matters most, and vendor partnerships for tactical use cases where the value of federation is meaningful but not strategic.

The role of regulators in shaping federated adoption

Regulator engagement with federated learning is itself shaping the trajectory of pharma adoption. The FDA, EMA, and other regulators have signaled interest in federated approaches as part of the broader AI regulatory framework but have not yet provided detailed guidance specific to federated learning use cases. Several patterns are emerging from regulator engagement that organizations evaluating federated learning should track.

Regulators are interested in federated learning as a privacy-preserving mechanism for real-world evidence generation, particularly for rare diseases where centralized data approaches are impractical. They are scrutinizing federated learning proposals for the same validation rigor they apply to centralized approaches, with additional attention to the distributed validation challenges. They are emphasizing transparency and explainability requirements that federated learning has to address, sometimes more carefully than centralized approaches given the distributed training data. And they are showing particular interest in cross-jurisdictional federated initiatives that demonstrate how privacy-preserving collaboration can work across regulatory regimes.

Organizations engaging with federated learning in regulated use cases benefit from early and structured regulator engagement — not just on the specific use case but on the broader federated approach being proposed. Regulators are still building their views, and organizations that contribute to the development of those views through credible technical proposals and well-documented validation evidence position themselves favorably in the eventual regulatory framework.

References